Drug development using human induced pluripotent stem cell derived retinal pigment epithelium
| Project/Area Number |
15K20295
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Ophthalmology
|
|---|
| Research Institution | Kawasaki Medical School |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2015-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | 網膜色素上皮細胞 / ヒトiPS細胞 / 網膜色素上皮 / 組織プラスミノーゲン活性化因子 |
|---|
| Outline of Final Research Achievements |
pharmacological effect and toxicity tests of tissue plasminogen activator (tPA) were evaluated using human induced pluripotent stem cell derived retinal pigment epithelium (hiPSC-RPE).RPE cell line and human fetal RPE were used as control. All RPE cultured with assorted tPA concentration were evaluated by cytotoxicity, morphological change, growth factor secretion, and RPE specific gene expression. HiPS-RPE and fetal RPE showed similar cytotoxicity and morphological changes, however the RPE cell line showed different changes. In growth factor secretion and RPE specific gene expression, All RPE were equivalent. HiPS-RPE showed drug resistance similar to fetal RPE, therefore it is possible that hiPS-RPE is a useful tool for drug development.
|
Report
(3 results)
Research Products
(3 results)
